RQ Bio discovers and develops long-acting monoclonal antibodies against seasonal influenza to provide immediate, powerful and lasting protection from severe viral disease for vulnerable people.

Founders

• Mike Westby · co-founder; CEO, Director
  He has more than 20 years of R&D pharma and biotech experience, including Roche and Pfizer, where he led the Anti-Infectives Research Group at Pfizer's Sandwich R&D site.
• Paul Kellam · co-founder; Chief Scientific Officer
  His scientific career spans the Wellcome Foundation, Kymab and academia, including the Wellcome Trust Sanger Institute and UCL.
• Jane K Osbourn OBE FMed Sc · co-founder; Scientific Advisor
  She was an early employee of Cambridge Antibody Technology, which became MedImmune and then part of AstraZeneca, where she contributed to phage-display technology and biologics discovery, and she chaired the UK BioIndustry Association from 2015 to 2019.
• Gavin Screaton · scientific and medical co-founder; Scientific Advisor
  He studied at Cambridge and Oxford, completed a DPhil at Oxford, and is Head of the Medical Sciences Division at the University of Oxford.

Business model

RQ Bio discovers antibody candidates and partners with large pharmaceutical companies for clinical development, manufacturing and commercialization, earning licensing economics such as upfront and milestone payments and royalties on sales.